Neuroendocrine carcinoma

This early-phase trial is testing an experimental therapy called DLL3-SAVVYZ-IL18 CAR T cells in people with advanced neuroendocrine cancers, including small cell lung cancer. The treatment involves reprogramming a patient's own immune cells to recognize and attack cancer cells t…

This phase 2 trial is testing whether adjusting the dose of the drug belinostat based on a person's genetics can make treatment safer and more effective for high-grade neuroendocrine carcinoma. About 60 adults will receive belinostat along with two other chemotherapy drugs, cispl…

Researchers are testing tarlatamab in people with advanced extrapulmonary small cell carcinoma or neuroendocrine carcinoma that has worsened after platinum-based chemotherapy. These rare cancers often carry high levels of a protein called DLL3, which tarlatamab targets by linking…

This early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…

This Phase 3 trial tests whether adding obrixtamig to standard chemotherapy helps people with advanced extrapulmonary neuroendocrine cancer live longer. About 390 adults will be randomly assigned to get either the combo or chemo alone. Obrixtamig is designed to help the immune sy…

This phase 2 trial is testing a drug called tarlatamab in 40 people with advanced small-cell lung cancer or other poorly differentiated neuroendocrine cancers. The drug is given by IV and aims to shrink tumors. Researchers will also study blood and tumor samples to understand why…

This early-phase study tests a new radioactive drug, 225Ac-ETN029, in 116 adults with advanced DLL3-positive cancers like small cell lung cancer or neuroendocrine tumors. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Pa…

This early-phase trial tests a new treatment called ML261 for people with advanced small cell lung cancer or certain neuroendocrine cancers that have not responded to standard treatments. ML261 is made from a patient's own immune cells, which are modified in a lab to better recog…

This study tests a new drug called ZL-1310 in adults with advanced neuroendocrine carcinomas (a type of solid tumor) that have worsened after platinum-based chemotherapy. The trial has two parts: Phase 1b checks safety and side effects, while Phase 2 looks at whether the drug shr…

This study is testing a treatment called BSJ019T in Japanese patients with liver cancer that cannot be removed by surgery and has not responded to standard treatments. The goal is to see if the treatment can control the cancer's growth and how safe it is. About 51 participants wi…

This study tests a drug called ifinatamab deruxtecan (I-DXd) in people with 13 types of advanced solid tumors that have come back or spread. The trial aims to see how well the drug shrinks tumors and what side effects it causes. About 520 participants will receive the drug intrav…

This study tests a new drug called CRN09682 in people with progressive metastatic neuroendocrine neoplasms and other solid tumors that have a specific marker (SST2). The trial has two phases: first, finding the safest dose, then testing that dose in more patients. About 150 parti…

This phase 2 trial tests BI 764532 (obrixtamig), an antibody-like drug designed to help the immune system attack cancer cells. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to prior treatments. The study compares two…

This study tests a new drug, peluntamig (PT217), in people with advanced neuroendocrine cancers like small cell lung cancer. The drug is designed to attach to two proteins (DLL3 and CD47) found on cancer cells, potentially helping the immune system attack them. The trial will fir…

This trial tests whether adding two drugs—surufatinib and serplulimab—to standard chemotherapy can help people with neuroendocrine carcinoma, a rare and aggressive cancer. The study enrolls adults who have not had prior treatment and measures how long the cancer stays under contr…

This study tests whether adding tivozanib (a drug that targets blood vessel growth) to atezolizumab (an immunotherapy) can help the immune system attack cancers that normally resist immunotherapy. The trial includes people with several cancer types like bile duct, pancreatic, pro…

This study tests a new drug called IDE849, alone or with other drugs, in people with cancers that have a protein called DLL3, including small cell lung cancer. The trial has two phases and aims to see if the drug is safe and shrinks tumors. About 208 participants who have already…

This early-phase study tests a new drug called HLX3901 in people with advanced small cell lung cancer or neuroendocrine carcinoma. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 138 adults aged 18 to 75 will take part.

This early-phase trial tests a new drug called ADCT-701 in adults with rare cancers like neuroendocrine tumors, adrenal cancer, and malignant peripheral nerve sheath tumors. The goal is to find the safest dose and see if it can shrink tumors or slow disease. Participants receive …

This early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…

This phase 2 trial tests a combination of two chemotherapy drugs (capecitabine and temozolomide) plus tiny radioactive beads delivered directly to the liver (Y90 radioembolization) in 70 people with grade 2 or 3 neuroendocrine tumors that have spread to the liver. The goal is to …

This early-stage trial is testing an experimental drug called HS-20108 in 502 people with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe dose and check for side effects. Researchers will also look for any signs that the drug might shr…

This study tests a new drug called repotrectinib in people with advanced solid tumors that have certain gene changes (ALK, ROS1, or NTRK). The trial has two parts: first, finding a safe dose, and second, seeing how well the drug shrinks tumors. About 500 adults with advanced canc…

This study tests a new drug that delivers radiation directly to cancer cells carrying a protein called DLL3, found in small cell lung cancer and other solid tumors. The trial enrolls 138 adults whose cancer has progressed after at least two prior treatments. The goal is to check …

This early-phase study tests whether an oral supplement called L-Citrulline is safe for preterm babies born at or before 30 weeks who have lung problems (BPD) or a serious gut condition (NEC). The goal is to see if raising low levels of a natural substance in the blood can reduce…

This early-phase trial tests a cancer-killing virus (SVV-001) injected directly into tumors, combined with two immunotherapy drugs (nivolumab and ipilimumab), in 36 adults with advanced neuroendocrine tumors that have worsened after standard treatment. The main goals are to find …

This phase 2 trial is testing a drug called tarlatamab in 60 adults with advanced extrapulmonary neuroendocrine carcinoma, a rare cancer that has come back after standard chemotherapy. Tarlatamab works by helping the body's immune cells find and attack cancer cells. The main goal…

This phase 2 trial tests a combination of three drugs—chidamide, sintilimab, and bevacizumab—in 34 people with advanced extrapulmonary neuroendocrine carcinoma that has worsened after first-line therapy. The goal is to see if this combo can shrink tumors or slow disease progressi…

This study tests a combination of two drugs, lenvatinib and pembrolizumab, in people with a rare and aggressive type of neuroendocrine tumor called well-differentiated grade 3 (WD G3). The goal is to see if the treatment can shrink tumors or stop them from growing. About 29 adult…

This study tests a new drug called LBL-024 combined with standard chemotherapy (etoposide plus platinum) as a first treatment for people with advanced neuroendocrine carcinoma. About 178 adults aged 18-75 will take part to see if the combination is safe and helps shrink tumors. T…

This Phase 3 trial is testing whether the drug tarlatamab can help people with advanced neuroendocrine carcinoma live longer compared to standard chemotherapy. The study plans to enroll 129 participants who have already received prior treatment. Tarlatamab is given as an infusion…

This study tests two experimental drugs, ZG006 and ZG005, given together by IV in people with advanced small cell lung cancer or neuroendocrine carcinoma. The trial aims to see if the combination is safe and can shrink tumors. About 350 adults aged 18 to 70 are being recruited at…

This study tests an experimental drug called ZG006 in people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments or cannot tolerate them. The main goals are to find a safe dose and check for side effects. About 54 adults aged 18 to 75 w…

This study tests a combination of two experimental drugs, ZGGS18 and ZG005, in people with advanced solid tumors (cervical, liver, neuroendocrine, or lung cancer) that no longer respond to standard treatments. The main goals are to check safety, find the best dose, and see if the…

This phase 2 trial tests whether the drug zanzalintinib, taken as a maintenance therapy after initial chemotherapy, can help delay cancer progression in people with high-grade neuroendocrine neoplasms. About 32 participants will receive the drug and be monitored for how long thei…

This early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human s…

This phase 2 trial is testing whether the immunotherapy drug dostarlimab can work better than standard chemotherapy as a first treatment for people with rare, advanced cancers that have a specific genetic flaw called dMMR/MSI. The study includes 120 adults with cancers like pancr…

This study tests a new biologic drug called ZG006 in people with advanced small cell lung cancer or neuroendocrine carcinoma. The trial has two parts: first, finding a safe dose (Phase 1), then testing how well it shrinks tumors (Phase 2). About 265 participants will receive ZG00…

This study tests whether a chemotherapy regimen called mFOLFIRINOX works better than the standard platinum-etoposide combination for people with a rare, fast-growing type of neuroendocrine cancer that has spread. About 218 adults with this cancer will be randomly assigned to one …

This early-phase trial is testing a radioactive tracer called FAPI-04 to see how well it lights up high-grade neuroendocrine tumors on PET/CT scans. The study will enroll 30 adults with these aggressive tumors to measure where the tracer goes in the body and how much it accumulat…

This study tests whether a new imaging agent called [18F]FAPI-74 can find certain cancers as well as or better than the standard PET tracer. About 320 adults with one of 11 cancer types (including pancreatic, liver, ovarian, and lung cancers) will receive both tracers and have th…

This study is testing a new type of PET scan that targets a protein called DLL3, found on some neuroendocrine cancer cells. The goal is to see if this scan can find tumors more accurately than current imaging methods. About 60 adults with suspected or confirmed neuroendocrine can…

This study compares giving cancer treatment at home versus in the clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves overall experience. About 220 participants will be randomly assigned to receive their reg…

This study looks back at medical records of 200 adults in Latin America with a rare and aggressive cancer called neuroendocrine carcinoma. Researchers want to understand how patients are diagnosed, what treatments they receive, and how their disease progresses over time. The goal…

This study uses a special PET scan to see how the experimental drug BI 764532 travels through the body and reaches tumors. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers who have run out of standard treatment options. The main goal is to mea…

This study analyzes tumor tissue from 797 people with relapsed small cell lung cancer to identify genetic subtypes. No drugs are tested here. Instead, the results may help match patients to future targeted therapy trials. Participants must have had prior platinum-based chemothera…

This study looks at very preterm babies to understand how feeding during blood transfusions affects blood flow and oxygen levels in their gut. Researchers will use non-invasive monitors to measure these changes in 270 infants. The goal is to find safer care practices that could l…

This study looks at how the intestines develop in premature and full-term babies up to 2 years old. Researchers will collect tissue, blood, and stool samples from infants already having intestinal surgery or scopes. The goal is to better understand normal development and diseases…

This study tests a new radioactive tracer called [18F]FTT to see how well it lights up pancreatic neuroendocrine tumors on a PET scan. Twelve adults with advanced tumors will receive one injection and have a whole-body scan. The goal is to measure tumor activity and compare it wi…

This study aims to collect tissue samples and health information from 300 adults with neuroendocrine neoplasms (NENs), including adrenocortical carcinoma. Researchers will follow participants over time to understand how these rare cancers grow and respond to treatments. The goal …